For more than a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations. The biology looked promising. Many cancers depend on oncogenes that "Bromo- and Extra-Terminal domain" (BET) proteins help activate, so blocking BET proteins should slow tumor growth.
from Medical Xpress - latest medical and health news stories https://ift.tt/zVejRhx
